These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 22162592)
1. Fatal infusion reactions to cetuximab: role of immunoglobulin e-mediated anaphylaxis. Pointreau Y; Commins SP; Calais G; Watier H; Platts-Mills TA J Clin Oncol; 2012 Jan; 30(3):334; author reply 335. PubMed ID: 22162592 [No Abstract] [Full Text] [Related]
2. Managing drug infusion reactions: focus on cetuximab monoclonal antibody therapy. Wilkes G Clin J Oncol Nurs; 2008 Jun; 12(3):530-2. PubMed ID: 18515254 [No Abstract] [Full Text] [Related]
3. Fatal infusion reaction to cetuximab: the need for predictive risk factors and safer patient selection. Tronconi MC; Sclafani F; Rimassa L; Carnaghi C; Personeni N; Santoro A J Clin Oncol; 2011 Aug; 29(23):e680-1. PubMed ID: 21690469 [No Abstract] [Full Text] [Related]
4. Manage infusion reactions from cetuximab. Becze E ONS Connect; 2008 Sep; 23(9):18-9. PubMed ID: 18807709 [No Abstract] [Full Text] [Related]
5. Fatal toxic epidermal necrolysis associated with cetuximab in a patient with colon cancer. Lin WL; Lin WC; Yang JY; Chang YC; Ho HC; Yang LC; Yang CH; Hung SI; Chung WH J Clin Oncol; 2008 Jun; 26(16):2779-80. PubMed ID: 18509187 [No Abstract] [Full Text] [Related]
6. Images in clinical medicine. Cetuximab-associated acneiform eruption. Moss JE; Burtness B N Engl J Med; 2005 Nov; 353(19):e17. PubMed ID: 16282170 [No Abstract] [Full Text] [Related]
12. Epidermal growth factor receptor inhibitors in colorectal cancer: it's time to get back on target. Meropol NJ J Clin Oncol; 2005 Mar; 23(9):1791-3. PubMed ID: 15677698 [No Abstract] [Full Text] [Related]
13. Pimecrolimus: a novel treatment for cetuximab-induced papulopustular eruption. Eiling E; Brandt M; Schwarz T; Hauschild A Arch Dermatol; 2008 Sep; 144(9):1236-8. PubMed ID: 18794482 [No Abstract] [Full Text] [Related]
14. Successful challenge with the fully human EGFR antibody panitumumab following an infusion reaction with the chimeric EGFR antibody cetuximab. Helbling D; Borner M Ann Oncol; 2007 May; 18(5):963-4. PubMed ID: 17488734 [No Abstract] [Full Text] [Related]
15. Papulo-pustular eruption during cetuximab treatment. Satta R; Cuccuru MA; Pirodda C; Cottoni F G Ital Dermatol Venereol; 2008 Feb; 143(1):87-8. PubMed ID: 18833056 [No Abstract] [Full Text] [Related]
16. Cicatricial ectropion associated with treatment of metastatic colorectal cancer with cetuximab. Garibaldi DC; Adler RA Ophthalmic Plast Reconstr Surg; 2007; 23(1):62-3. PubMed ID: 17237696 [TBL] [Abstract][Full Text] [Related]
19. Infusion reactions to the chimeric EGFR inhibitor cetuximab--change to the fully human anti-EGFR monoclonal antibody panitumumab is safe. Resch G; Schaberl-Moser R; Kier P; Kopetzky G; Scheithauer W; Sliwa T; Greil R; Nösslinger T; Mayrbäurl B; Thaler J Ann Oncol; 2011 Feb; 22(2):486-7. PubMed ID: 21239398 [No Abstract] [Full Text] [Related]
20. Retrospective chart review of severe infusion reactions with rituximab, cetuximab, and bevacizumab in community oncology practices: assessment of clinical consequences. Schwartzberg LS; Stepanski EJ; Fortner BV; Houts AC Support Care Cancer; 2008 Apr; 16(4):393-8. PubMed ID: 17909865 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]